2016
DOI: 10.3747/co.23.3191
|View full text |Cite
|
Sign up to set email alerts
|

Chemotherapy in Recurrent Advanced Non-Small-Cell Lung Cancer After Adjuvant Chemotherapy

Abstract: Introduction Despite adjuvant systemic therapy in patients with completely resected non-small-cell lung cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
20
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 26 publications
(22 citation statements)
references
References 16 publications
2
20
0
Order By: Relevance
“…Owing to several limitations associated with early stage diagnosis, majority of lung cancer patients diagnosed at the median or advanced stage. Additionally, due to the moderate progress provided by chemotherapeutics and the development of drug resistance 1,2 , the use of natural products for lung cancer treatment has attracted the attention 5 . In this study, chemical examination of Phoma sp .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Owing to several limitations associated with early stage diagnosis, majority of lung cancer patients diagnosed at the median or advanced stage. Additionally, due to the moderate progress provided by chemotherapeutics and the development of drug resistance 1,2 , the use of natural products for lung cancer treatment has attracted the attention 5 . In this study, chemical examination of Phoma sp .…”
Section: Discussionmentioning
confidence: 99%
“…The main types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer. The major lung cancer NSCLC includes various types such as squamous cell carcinoma, large cell carcinoma, adenocarcinoma, pleomorphic, carcinoid tumor, and salivary gland carcinoma 1 . The metastasis-related death found to be as high as 90% of all lung cancer mortality 2 .…”
Section: Introductionmentioning
confidence: 99%
“…6 The vast majority of patients with advanced NSCLC are considered surgically 'unresectable'. [7][8][9][10] In Stage IIIB/IV, the effectiveness of various platinum-based drug combinations are similar, with response rates ranging from 30-40%, a duration of <6 months, and median survival of approximately 12 months. 7 In particular, the selection of resistant neoplastic clones by means of somatic evolution and the substantial lack of recognised predictive/prognostic biomarkers are related to treatment failures.…”
Section: Introductionmentioning
confidence: 99%
“…Since found by Rosenbery in 1969, platinum was widely used in clinical practice including chemotherapeutics of NSCLC, which benefited a lot of incipient or advanced patients [ 53 , 54 ]. Tumor cells, which proliferated more rapidly than normal ones, could be influenced directly by anticarcinogen, thus stopping equal division of DNA to next generation [ 55 ].…”
Section: Introductionmentioning
confidence: 99%